| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NTLA | Common Stock | Sale | $2,476,268 | -29,071 | -3.8% | $85.18 | 736,030 | 11 Jun 2021 | See Footnote | F1, F2, F9 |
| transaction | NTLA | Common Stock | Sale | $161,212 | -1,875 | -0.25% | $85.98 | 734,155 | 11 Jun 2021 | See Footnote | F1, F3, F9 |
| transaction | NTLA | Common Stock | Sale | $1,399,895 | -16,293 | -2.2% | $85.92 | 717,862 | 14 Jun 2021 | See Footnote | F1, F4, F9 |
| transaction | NTLA | Common Stock | Sale | $4,112,910 | -47,422 | -6.6% | $86.73 | 670,440 | 14 Jun 2021 | See Footnote | F1, F5, F9 |
| transaction | NTLA | Common Stock | Sale | $8,169,700 | -93,102 | -14% | $87.75 | 577,338 | 14 Jun 2021 | See Footnote | F1, F6, F9 |
| transaction | NTLA | Common Stock | Sale | $1,180,508 | -13,309 | -2.3% | $88.70 | 564,029 | 14 Jun 2021 | See Footnote | F1, F7, F9 |
| transaction | NTLA | Common Stock | Sale | $58,280 | -653 | -0.12% | $89.25 | 563,376 | 14 Jun 2021 | 1See Footnote | F1, F8, F9 |
| Id | Content |
|---|---|
| F1 | Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP"), is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. The shares were sold by Atlas IX pursuant to a Rule 10b5-1 plan adopted by Atlas IX on March 1, 2021 |
| F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.90 - $85.89, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) of this Form 4. |
| F3 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.90 - $86.08, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) of this Form 4. |
| F4 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.23 - $86.21, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) of this Form 4. |
| F5 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.23 - $87.22, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (5) of this Form 4. |
| F6 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.23 - $88.22, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (6) of this Form 4. |
| F7 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.23 - $89.17, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (7) of this Form 4. |
| F8 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.25 - $89.26, inclusive. The reporting person undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (8) of this Form 4. |
| F9 | Represents shares held directly by Atlas IX. The general partner of Atlas IX is AVA IX LP. AVA IX LLC is the general partner of AVA IX LP. Dr. Formela is a member of AVA IX LLC and disclaims Section 16 beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. |
Exhibit 24 - Power of Attorney (incorporated by reference to Exhibit 24, Power of Attorney, filed on Form 4 with the SEC on March 13, 2017 by the reporting person)